HRP20110487T1 - Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a - Google Patents

Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a Download PDF

Info

Publication number
HRP20110487T1
HRP20110487T1 HR20110487T HRP20110487T HRP20110487T1 HR P20110487 T1 HRP20110487 T1 HR P20110487T1 HR 20110487 T HR20110487 T HR 20110487T HR P20110487 T HRP20110487 T HR P20110487T HR P20110487 T1 HRP20110487 T1 HR P20110487T1
Authority
HR
Croatia
Prior art keywords
polymer conjugate
hmgb1
hmgb1 box
diseases
box
Prior art date
Application number
HR20110487T
Other languages
English (en)
Croatian (hr)
Inventor
Traversa Silvio
Lorenzetto Chiara
Mainero Valentina
Morena Sebastiano
Fumero Silvano
Beccaria Luca
Original Assignee
Creabilis Therapeutics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38969804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110487(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics S.R.L. filed Critical Creabilis Therapeutics S.R.L.
Publication of HRP20110487T1 publication Critical patent/HRP20110487T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
HR20110487T 2006-09-15 2007-09-14 Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a HRP20110487T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06019362 2006-09-15
US90477607P 2007-03-05 2007-03-05
PCT/EP2007/008029 WO2008031612A1 (en) 2006-09-15 2007-09-14 Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1

Publications (1)

Publication Number Publication Date
HRP20110487T1 true HRP20110487T1 (hr) 2011-08-31

Family

ID=38969804

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110487T HRP20110487T1 (hr) 2006-09-15 2007-09-14 Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a

Country Status (10)

Country Link
US (3) US8546547B2 (enExample)
EP (1) EP2068935B8 (enExample)
JP (3) JP2010503630A (enExample)
AU (1) AU2007296843C1 (enExample)
CA (1) CA2663300C (enExample)
HR (1) HRP20110487T1 (enExample)
IL (1) IL197441A (enExample)
MX (1) MX2009002820A (enExample)
PL (1) PL2068935T3 (enExample)
WO (1) WO2008031612A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
CN101691580B (zh) * 2009-09-28 2012-02-15 中国人民解放军第三军医大学 人HMGB1 A box和酸性尾端的新型融合蛋白及其应用
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
US20110123483A1 (en) * 2009-11-23 2011-05-26 Deutsches Krebsforschungszentrum Hmgb1 for cancer treatment
US8981025B2 (en) 2011-02-10 2015-03-17 Corning Incorporated Polymerizable catonic peptide monomers and polymers
EP3358011B1 (en) 2011-04-26 2020-03-04 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
WO2014016417A1 (en) 2012-07-26 2014-01-30 Ospedale San Raffaele Srl Hmgb1 variants and uses thereof
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
EP3386529A2 (en) 2015-12-11 2018-10-17 Ruprecht-Karls-Universität Heidelberg Combined preparations of pkm2 modulators and hmgb1
AU2018213671B2 (en) 2017-01-27 2024-06-06 Osaka University Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
AU2018376452A1 (en) 2017-12-01 2020-06-25 Osaka University Ectodermal mesenchymal stem cells and method for producing same
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
JP2022504139A (ja) * 2018-10-05 2022-01-13 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのｈｍｇｂ１タンパク質誘導体
ES3041501T3 (en) * 2018-10-25 2025-11-12 The Univ Of Osaka Hmgb1 derived peptide for treating or preventing a cartilage disorder
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
AU2020407267A1 (en) 2019-12-18 2022-06-16 F. Hoffmann-La Roche Ag Methods of sequencing by synthesis using a consecutive labeling scheme

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
JP4259868B2 (ja) 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
BR0209689A (pt) 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
JP2006510619A (ja) * 2002-11-20 2006-03-30 クリティカル セラピューティクス，インコーポレイテッド 抗炎症剤としてのｈｍｇｂ断片の使用
WO2004056852A2 (en) 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
EP1613274B1 (en) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
CA2579094C (en) 2004-09-03 2014-12-02 Creabilis Therapeutics S.P.A. Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
KR101379693B1 (ko) 2005-08-25 2014-04-10 크리어빌리스 쎄라퓨틱스 에스.피.에이. Ｋ-252ａ 및 그의 유도체의 중합체 컨쥬게이트

Also Published As

Publication number Publication date
CA2663300C (en) 2014-10-07
AU2007296843C1 (en) 2012-08-16
US20170304398A1 (en) 2017-10-26
EP2068935A1 (en) 2009-06-17
US8546547B2 (en) 2013-10-01
JP2017200930A (ja) 2017-11-09
EP2068935B8 (en) 2011-09-14
IL197441A0 (en) 2009-12-24
JP2015193646A (ja) 2015-11-05
US20140065094A1 (en) 2014-03-06
AU2007296843A1 (en) 2008-03-20
EP2068935B1 (en) 2011-04-13
MX2009002820A (es) 2009-06-04
US20090324677A1 (en) 2009-12-31
PL2068935T3 (pl) 2011-11-30
CA2663300A1 (en) 2008-03-20
IL197441A (en) 2013-07-31
US9707298B2 (en) 2017-07-18
JP2010503630A (ja) 2010-02-04
WO2008031612A1 (en) 2008-03-20
HK1134779A1 (en) 2010-05-14
AU2007296843B2 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
JP2010503630A5 (enExample)
JP6995933B2 (ja) インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
Deng et al. Microenvironment-responsive smart hydrogels with antibacterial activity and immune regulation for accelerating chronic wound healing
JP5105554B2 (ja) 癌を処置するためのペグ化ｉｌ−１０の使用
Ydens et al. Acute injury in the peripheral nervous system triggers an alternative macrophage response
RS66991B1 (sr) Peptidni inhibitori interleukin-23 receptora i njihova primena u lečenju inflamatornih bolesti
RU2458070C2 (ru) Конъюгаты с полимером а-бокса hmgb1 и вариантов а-бокса hmgb1
JP2017200930A (ja) ＨＭＢＧ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
JP2010531139A5 (enExample)
JP2008511300A5 (enExample)
EP1425028A2 (en) Use of il-18 inhibitors for the treatement or prevention of sepsis
CN102203118B (zh) 白介素-15活性的肽拮抗剂
WO2018171406A1 (zh) 选择性tnfr1拮抗肽在制备预防和治疗类风湿性关节炎的药物中的应用
RU2018127330A (ru) Композиция, включающая агонист рецептора glp-1 и агонист глюкагонового рецептора, и ее применение
WO2008040190A1 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
CN113039194A (zh) 具有免疫调节特性的肽
CN108025040A (zh) 使用白介素-10治疗疾病和病症的方法
TW201822767A (zh) 用於局部給予toll樣受體激動劑之嵌段共聚物系統
CN111788217A (zh) 白介素-15活性的拮抗剂肽
US20250381279A1 (en) Cytotoxin-ccl8 peptide constructs and uses thereof
Yoshioka et al. Development of a novel DDS for site-specific PEGylated proteins
AU784768B2 (en) Methods for treating cytokine mediated diseases
ES2493391T3 (es) Uso de IL-6 en la preparación de composiciones farmacéuticas para tratar y prevenir lesiones hepáticas
Dash Elastin-like polypeptide mediated proangiogenic and anti-inflammatory gene therapy for critical limb ischemia
AU2002309887B2 (en) Use of IL-18 inhibitors for the treatment or prevention of sepsis